{"id":"W1496017371","doi":"","title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bausch Health (Canada)","funders":"","keywords":"Medicine; Imiquimod; Actinic keratosis; Tolerability; Scalp; Placebo; Dermatology; Adverse effect; Clinical endpoint; Randomized controlled trial; Internal medicine; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004121394,0.00140859,0.003296193,0.0008403483,0.0005553045,0.0008966466,0.001089855,0.002141371,0.005550243],"category_scores_gemma":[0.00181615,0.0008822121,0.002097331,0.0007036512,0.0009988752,0.0008392252,0.0003501319,0.001824616,0.0006688391],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007322008,"about_ca_system_score_gemma":0.001624751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001034004,"about_ca_topic_score_gemma":0.002839384,"domain_scores_codex":[0.9986886,0.0006836992,0.000126017,0.0001858128,0.0001511119,0.0001648133],"domain_scores_gemma":[0.9988666,0.0003013675,0.0003767289,0.0000670977,0.000114975,0.0002731985],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9208215,0.02467297,0.0006746366,0.001843111,0.001445263,0.00005435189,0.00008853282,0.0002464316,0.01363219,0.0001366681,0.0008662737,0.03551807],"study_design_scores_gemma":[0.8985453,0.0976776,0.001641342,0.0000537525,0.0005684082,0.0000273285,0.0000125951,0.000109924,0.0005832949,0.00003770092,0.0007320983,0.00001057558],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9465251,0.02289519,0.002212683,0.0008050151,0.000847504,0.02273492,0.00152572,0.0001957973,0.002258052],"genre_scores_gemma":[0.9545763,0.0124679,0.005494851,0.001755084,0.0008592705,0.02047641,0.001288705,0.00003364098,0.003048025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005550243,"threshold_uncertainty_score":0.02179629,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07708493520410008,"score_gpt":0.3597769123377111,"score_spread":0.282691977133611,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}